Tokyo, Japan, Apr 17, 2006 - (JCN Newswire) - Chugai Pharmaceutical Co., Ltd. (TSE: 4519) announced that the company filed a new drug application (NDA) for erlotinib for advanced or recurrent non-small cell lung cancer (NSCLC) with the Japanese Ministry of Health, Labour and Welfare (MHLW) as of April 14, 2006.
